Chronic Heart Failure in Russian Federation: What Do We Know and What to Do

The analysis is presented, of the three epidemiologic studies (EPOCHA-CHF, EPOCHA-Hospital-CHF, EPOCHA-Decompensation-CHF). In 16 years, prevalence of chronic heart failure (CHF) in Russia increased from 4,9% (1998) to 10,2% (2014), p=0,01. However, number of CHF patients with III-IV FC NYHA increased more dramatically: from 1,2% (1998) to 4,1% (2014), p=0,002. This happened due to significant increse of the age of patients selection from 64,0±11, 9 y.o. (1998) to 69,9±12,2 y.o. (2014), p=0,02; increase of the weight of etiological causes of ischemic heart disease and myocardial infarction. Overall mortality of the patients with any CHF is 6% per year. This value depends on low rate of prescription of RAAS blockers and beta-blockers during outpatient stage, with usage of low dosages of medications that does not control BP and heartrate. Patients with CHF decompensation led to hospitalization are significantly older than in general population (72,9±10,5 y.o.), and gender differences are for benefit of women, as in general population. 58,2% of hospitalized patients were admitted with noncontrolled hypertension, and in 70,5% there was heartrate higher than 80 bpm. Overall mortality of CHF patients was 25,1% (46,4% died in 1 year with the formed hypotension and 22,1% with retained level of BP). Hospital mortality was 6,8%. Mortality risks increased by repeated admittances for decompensation, absence of RAAS blockers and beta-blockers in management.